Neuronetics, Inc.(STIM)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,251 of 2,962 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
STIM Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for Neuronetics, Inc. (STIM), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores STIM at 36.9/100 on a 32-signal composite quality model, placing it at rank #2,251 of 2,962 stocks — the bottom half of the AI-ranked universe. STIM scores in the top quartile across revenue growth (93.6). Areas of concern include institutional flow (4.1) and balance sheet strength (9.9), which score below median versus the broader universe. Shareholder dilution risk is elevated at 26.2/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Neuronetics, Inc. reports quarterly revenue of $41.6M, net income of $-3.4M, free cash flow of $-1.4M. Top institutional holders of STIM by reported 13-F value include Madryn Asset Management, UBS Group AG, WEXFORD CAPITAL, based on the most recent SEC filings. STIM trades on the Nasdaq exchange and files with the SEC under CIK 1227636. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate STIM daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Neuronetics, Inc. directly from SEC EDGAR. Neuronetics, Inc.'s 13F Pro composite quality score has ranged between 8 and 38 since 2021, currently 36.9 — an improving long-term trajectory across 68 quarterly and live scoring snapshots.
Revenue
Q2 2026
$41.6M
Net Income
Q2 2026
$-3.4M
Free Cash Flow
Q2 2026
$-1.4M
ROIC
Q2 2026
-7.6%
D/E Ratio
Q2 2026
3.45
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
+99.2% YoYNet Income
+10.8% YoYOperating Income
+9.0% YoYEPS (Diluted)
+57.2% YoYTotal Assets
+0.5% YoYTotal Debt
+19.3% YoYOp. Cash Flow
+34.3% YoYFree Cash Flow
+34.8% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $149.2M +99.2% | $74.9M +5.0% | $71.3M +9.4% | $65.2M +17.9% | $55.3M +12.3% | $49.2M |
| Net Income | $-39.0M +10.8% | $-43.7M -44.8% | $-30.2M +18.8% | $-37.2M -19.1% | $-31.2M -13.6% | $-27.5M |
| Operating Income | $-31.4M +9.0% | $-34.6M -13.1% | $-30.6M +13.0% | $-35.1M -27.4% | $-27.6M -23.6% | $-22.3M |
| EPS (Diluted) | $-0.59 +57.2% | $-1.38 -31.4% | $-1.05 +23.9% | $-1.38 -13.1% | $-1.22 +16.4% | $-1.46 |
| Total Assets | $141.6M +0.5% | $140.9M +21.6% | $115.8M -0.9% | $116.9M -17.2% | $141.2M +79.5% | $78.7M |
| Total Debt | $65.8M +19.3% | $55.2M -7.0% | $59.3M +20.8% | $49.1M +38.9% | $35.3M +2.1% | $34.6M |
| Operating Cash Flow | $-20.4M +34.3% | $-31.0M +3.2% | $-32.0M -4.2% | $-30.7M -9.8% | $-28.0M +1.4% | $-28.4M |
| Free Cash Flow | $-21.2M +34.8% | $-32.5M +5.7% | $-34.4M -1.2% | $-34.0M -12.1% | $-30.3M -4.2% | $-29.1M |
Get alerted when STIM's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Neuronetics, Inc. including:
Top Institutional Holders of STIM
Madryn Asset Management, LP
$24.1M18,540,488 shUBS Group AG
$3.0M2,279,099 shWEXFORD CAPITAL LP
$2.6M2,002,625 shFourWorld Capital Management LLC
$2.3M1,744,142 shLane Generational LLC
$2.1M1,633,372 shVANGUARD CAPITAL MANAGEMENT LLC
$2.0M1,507,097 shMASTERS CAPITAL MANAGEMENT LLC
$1.3M1,000,000 shAdvisorShares Investments LLC
$965.6K742,795 shIkarian Capital, LLC
$911.5K701,182 shBlackRock, Inc.
$775.6K596,622 sh
| Fund | Value | Shares |
|---|---|---|
| Madryn Asset Management, LP | $24.1M | 18,540,488 |
| UBS Group AG | $3.0M | 2,279,099 |
| WEXFORD CAPITAL LP | $2.6M | 2,002,625 |
| FourWorld Capital Management LLC | $2.3M | 1,744,142 |
| Lane Generational LLC | $2.1M | 1,633,372 |
| VANGUARD CAPITAL MANAGEMENT LLC | $2.0M | 1,507,097 |
| MASTERS CAPITAL MANAGEMENT LLC | $1.3M | 1,000,000 |
| AdvisorShares Investments LLC | $965.6K | 742,795 |
| Ikarian Capital, LLC | $911.5K | 701,182 |
| BlackRock, Inc. | $775.6K | 596,622 |
Companies Similar to STIM
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
electroCore, Inc.
EXAGEN INC.
Ovid Therapeutics Inc.
Cue Biopharma, Inc.
Starling Oncology, Inc.
Journey Medical Corp
Lineage Cell Therapeutics, Inc.
DBV Technologies S.A.
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put STIM on your watchlist
Track score changes the day Neuronetics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is STIM a good stock to buy?
13F Pro's AI-powered analysis of Neuronetics, Inc. (STIM) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for STIM are available on the STIM stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. STIM is classified as a small company.
Which hedge funds own STIM?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling STIM. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Neuronetics, Inc.'s investment landscape.